This Plain Language Summary of Publication article (PLSP) from Future Oncology tested nab-sirolimus in patients with malignant perivascular epithelioid cell tumors (malignant PEComa), a rare advanced cancer. Researchers examined whether the treatment could shrink tumors, prevent cancer growth or spread, and assessed potential side effects.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.